Q&A: Sanofi’s R&D head re­flects on his first year, a post-Dupix­ent fu­ture, and find­ing an iden­ti­ty

Al­most a year ago, Sanofi made his­to­ry for the wrong rea­sons.

Last Oc­to­ber, CEO Paul Hud­son an­nounced strate­gic changes in­clud­ing boost­ing R&D spend­ing and pulling …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER